NCBS Home page
Accession List
Pathway List
Search
Authorized Users
Help
News archives

Enter a Search String

Special character and space not allowed in the query term. Search string should be at least 2 characters long.
Search in: Search for Match By


 
Result: 1 - 19 of 19 rows are displayed

Molecule List for pathway PKC (Pathway Number 138) in Accession PKC_turnover (Accession Number 26)

Default ordering is done according to Pathway Number. Table headers can be used for changing the default ordering.
arrow indicates that ordering is done according to ascending or descending order.
The entries are grouped according to Pathway Number and are alternately color coded using  and  color.
  NameAccession
Type
Initial
Conc.

(uM)
Volume
(fL)
BufferedSum Total Of
1 AAPathway5.51000No
    Arachidonic Acid. This messenger diffuses through membranes as well as cytosolically, has been suggested as a possible retrograde messenger at synapses. Based on simulations the AA settles to around 5.5 uM under resting conditions.
2 CaPathway0.081000No
    This calcium pool is treated as being buffered to a steady 0.08 uM, which is the resting level.
3 DAGPathway11.661000No
    Baseline in model is 11.661 uM. DAG is pretty nasty to estimate. In this model we just hold it fixed at this baseline level. Data sources are many and varied and sometimes difficult to reconcile. Welsh and Cabot 1987 JCB 35:231-245: DAG degradation Bocckino et al JBC 260(26):14201-14207: hepatocytes stim with vasopressin: 190 uM. Bocckino et al 1987 JBC 262(31):15309-15315: DAG rises from 70 to 200 ng/mg wet weight, approx 150 to 450 uM. Prescott and Majerus 1983 JBC 258:764-769: Platelets: 6 uM. Also see Rittenhouse-Simmons 1979 J Clin Invest 63. Sano et al JBC 258(3):2010-2013: Report a nearly 10 fold rise. Habenicht et al 1981 JBC 256(23)12329-12335: 3T3 cells with PDGF stim: 27 uM Cornell and Vance 1987 BBA 919:23-36: 10x rise from 10 to 100 uM. Summary: I see much lower rises in my PLC models, but the baseline could be anywhere from 5 to 100 uM. I have chosen about 11 uM based on the stimulus -response characteristics from the Schaechter and Benowitz paper and the Shinomura et al papers.
4 degraded-PKCPathway01000Yes
    This represents the ubiquitination and eventual removal of the PKC. See Lu et al 1998 Mol Cell Biol 18(2):839-845
5 PKC-AA*Pathway01000No
    This is the membrane-bound and active form of the PKC-AA complex.
6 PKC-activePathway01000No PKC-DAG-AA*
 PKC-Ca-memb*
 PKC-Ca-AA*
 PKC-DAG-memb*
 PKC-basal*
 PKC-AA*
    This is the total active PKC. It is the sum of the respective activities of PKC-basal* PKC-Ca-memb* PKC-DAG-memb* PKC-Ca-AA* PKC-DAG-AA* PKC-AA* I treat PKC here in a two-state manner: Either it is in an active state (any one of the above list) or it is inactive. No matter what combination of stimuli activate the PKC, I treat it as having the same activity. The scaling comes in through the relative amounts of PKC which bind to the respecive stimuli. The justification for this is the mode of action of PKC, which like most Ser/Thr kinases has a kinase domain normally bound to and blocked by a regulatory domain. I assume that all the activators simply free up the kinase domain. A more general model would incorporate a different enzyme activity for each combination of activating inputs, as well as for each substrate. The current model seems to be a decent and much simpler approximation for the available data. One caveat of this way of representing PKC is that the summation procedure assumes that PKC does not saturate with its substrates. If this assumption fails, then the contributing PKC complexes would experience changes in availability which would affect their balance. Given the relatively low percentage of PKC usually activated, and its high throughput as an enzyme, this is a safe assumption under physiological conditions.
7 PKC-basal*Pathway01000No
    This is the basal PKC activity which contributes about 2% to the maximum.
8 PKC-CaPathway01000No
    This intermediate is strongly indicated by the synergistic activation of PKC by combinations of DAG and Ca, as well as AA and Ca. PKC by definition also has a direct Ca-activation, to which this also contributes.
9 PKC-Ca-AA*Pathway01000No
    Membrane bound and active complex of PKC, Ca and AA.
10 PKC-Ca-DAGPathway01000No
    This is the active PKC form involving Ca and DAG. It has to translocate to the membrane.
11 PKC-Ca-memb*Pathway01000No
    This is the direct Ca-stimulated activity of PKC.
12 PKC-cytosolicPathway11000No
    Marquez et al J. Immun 149,2560(92) est 1e6/cell for chromaffin cells Kikkawa et al 1982 JBC 257(22):13341 have PKC levels in brain at about 1 uM. The cytosolic form is the inactive PKC. This is really a composite of three isoforms: alpha, beta and gamma which have slightly different properties and respond to different combinations of Ca, AA and DAG.
13 PKC-DAGPathway01000No
    This is a DAG-bound intermediate used in synergistic activation of PKC by DAG and AA.
14 PKC-DAG-AAPathway01000No
    Complex of PKC, DAG and AA giving rise to synergistic activation of PKC by DAG and AA at resting Ca.
15 PKC-DAG-AA*Pathway01000No
    Membrane translocated form of PKC-DAG-AA complex.
16 PKC-DAG-memb*Pathway01000No
    Active, membrane attached form of Ca.DAG.PKC complex.
17 PKC-RNAPathway11000Yes
    Just a unity concentration for convenience. The rate limiting step is the PKC-synthesis reaction.
18 PKC-substratePathway01000No
    This molecule represents a generic PKC substrate.
19 PKC-substrate*Pathway01000No
    This is the phosphorylated form of a generic PKC substrate.

 
Result: 1 - 19 of 19 rows are displayed



Database compilation and code copyright (C) 2005, Upinder S. Bhalla and NCBS/TIFR
This Copyright is applied to ensure that the contents of this database remain freely available. Please see FAQ for details.